Fractalkine signaling in regulation of insulin secretion: Mechanisms and potential therapeutic implications?

Brigid Gregg, Carey N. Lumeng, Ernesto Bernal Mizrachi

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Fractalkine is a chemokine, which has been shown to play important roles in metabolic disease in both animal models and humans. Fractalkine is a key player in the accumulation of atherosclerotic plaques, and fractalkine receptor (CX3CR1) mutations have been implicated in obesity. Serum fractalkine levels have been found to be elevated in type 2 diabetic patients, but the role of fractalkine signaling on the pancreatic β cell was unclear. Recently published findings in April 2013 issue of the journal Cell by Lee and Olefsky et al. have implicated fractalkine in β-cell insulin secretion. They demonstrate that Cx3cr1 knockout mice have impaired glucose tolerance resulting from decreased insulin secretion. In addition, fractalkine administration improved glucose tolerance and induced insulin secretion. This modulation of insulin secretion was proposed to result from an increase in intracellular calcium and potentiation of insulin secretion, which occurs in a Gαi and MEKdependent manner. They also found that Cx3cr1 knockout animals had transcriptional repression of genes important for β-cell function, specifically NeuroD, via induction of ICER-1. One important issue that remains unresolved is how CX3CR1 signaling regulates the potentiation of calcium influx and the distal events in insulin exocytosis. Finally, testing the effects of fractalkine treatment on proliferation and survival in vivo during regenerative conditions would be critical to determine the potential use of this chemokine in diabetes. While these exciting results open the possibility for new therapeutics, there are some concerns about a potential risk for exacerbation of atherosclerosis.

Original languageEnglish (US)
Article numbere27861
JournalIslets
Volume6
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Chemokine CX3CL1
Insulin
Chemokines
Therapeutics
Calcium
Glucose Intolerance
Metabolic Diseases
Exocytosis
Atherosclerotic Plaques
Knockout Mice
Atherosclerosis
Animal Models
Obesity
Glucose
Mutation
Survival

Keywords

  • CX3CL1
  • CX3CR1
  • Diabetes
  • Fractalkine
  • Insulin
  • Insulin secretion
  • Islets
  • β-cell

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Fractalkine signaling in regulation of insulin secretion : Mechanisms and potential therapeutic implications? / Gregg, Brigid; Lumeng, Carey N.; Bernal Mizrachi, Ernesto.

In: Islets, Vol. 6, No. 1, e27861, 2014.

Research output: Contribution to journalComment/debate

@article{db17daac887a44558c0e41263230a9b9,
title = "Fractalkine signaling in regulation of insulin secretion: Mechanisms and potential therapeutic implications?",
abstract = "Fractalkine is a chemokine, which has been shown to play important roles in metabolic disease in both animal models and humans. Fractalkine is a key player in the accumulation of atherosclerotic plaques, and fractalkine receptor (CX3CR1) mutations have been implicated in obesity. Serum fractalkine levels have been found to be elevated in type 2 diabetic patients, but the role of fractalkine signaling on the pancreatic β cell was unclear. Recently published findings in April 2013 issue of the journal Cell by Lee and Olefsky et al. have implicated fractalkine in β-cell insulin secretion. They demonstrate that Cx3cr1 knockout mice have impaired glucose tolerance resulting from decreased insulin secretion. In addition, fractalkine administration improved glucose tolerance and induced insulin secretion. This modulation of insulin secretion was proposed to result from an increase in intracellular calcium and potentiation of insulin secretion, which occurs in a Gαi and MEKdependent manner. They also found that Cx3cr1 knockout animals had transcriptional repression of genes important for β-cell function, specifically NeuroD, via induction of ICER-1. One important issue that remains unresolved is how CX3CR1 signaling regulates the potentiation of calcium influx and the distal events in insulin exocytosis. Finally, testing the effects of fractalkine treatment on proliferation and survival in vivo during regenerative conditions would be critical to determine the potential use of this chemokine in diabetes. While these exciting results open the possibility for new therapeutics, there are some concerns about a potential risk for exacerbation of atherosclerosis.",
keywords = "CX3CL1, CX3CR1, Diabetes, Fractalkine, Insulin, Insulin secretion, Islets, β-cell",
author = "Brigid Gregg and Lumeng, {Carey N.} and {Bernal Mizrachi}, Ernesto",
year = "2014",
doi = "10.4161/isl.27861",
language = "English (US)",
volume = "6",
journal = "Islets",
issn = "1938-2014",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Fractalkine signaling in regulation of insulin secretion

T2 - Mechanisms and potential therapeutic implications?

AU - Gregg, Brigid

AU - Lumeng, Carey N.

AU - Bernal Mizrachi, Ernesto

PY - 2014

Y1 - 2014

N2 - Fractalkine is a chemokine, which has been shown to play important roles in metabolic disease in both animal models and humans. Fractalkine is a key player in the accumulation of atherosclerotic plaques, and fractalkine receptor (CX3CR1) mutations have been implicated in obesity. Serum fractalkine levels have been found to be elevated in type 2 diabetic patients, but the role of fractalkine signaling on the pancreatic β cell was unclear. Recently published findings in April 2013 issue of the journal Cell by Lee and Olefsky et al. have implicated fractalkine in β-cell insulin secretion. They demonstrate that Cx3cr1 knockout mice have impaired glucose tolerance resulting from decreased insulin secretion. In addition, fractalkine administration improved glucose tolerance and induced insulin secretion. This modulation of insulin secretion was proposed to result from an increase in intracellular calcium and potentiation of insulin secretion, which occurs in a Gαi and MEKdependent manner. They also found that Cx3cr1 knockout animals had transcriptional repression of genes important for β-cell function, specifically NeuroD, via induction of ICER-1. One important issue that remains unresolved is how CX3CR1 signaling regulates the potentiation of calcium influx and the distal events in insulin exocytosis. Finally, testing the effects of fractalkine treatment on proliferation and survival in vivo during regenerative conditions would be critical to determine the potential use of this chemokine in diabetes. While these exciting results open the possibility for new therapeutics, there are some concerns about a potential risk for exacerbation of atherosclerosis.

AB - Fractalkine is a chemokine, which has been shown to play important roles in metabolic disease in both animal models and humans. Fractalkine is a key player in the accumulation of atherosclerotic plaques, and fractalkine receptor (CX3CR1) mutations have been implicated in obesity. Serum fractalkine levels have been found to be elevated in type 2 diabetic patients, but the role of fractalkine signaling on the pancreatic β cell was unclear. Recently published findings in April 2013 issue of the journal Cell by Lee and Olefsky et al. have implicated fractalkine in β-cell insulin secretion. They demonstrate that Cx3cr1 knockout mice have impaired glucose tolerance resulting from decreased insulin secretion. In addition, fractalkine administration improved glucose tolerance and induced insulin secretion. This modulation of insulin secretion was proposed to result from an increase in intracellular calcium and potentiation of insulin secretion, which occurs in a Gαi and MEKdependent manner. They also found that Cx3cr1 knockout animals had transcriptional repression of genes important for β-cell function, specifically NeuroD, via induction of ICER-1. One important issue that remains unresolved is how CX3CR1 signaling regulates the potentiation of calcium influx and the distal events in insulin exocytosis. Finally, testing the effects of fractalkine treatment on proliferation and survival in vivo during regenerative conditions would be critical to determine the potential use of this chemokine in diabetes. While these exciting results open the possibility for new therapeutics, there are some concerns about a potential risk for exacerbation of atherosclerosis.

KW - CX3CL1

KW - CX3CR1

KW - Diabetes

KW - Fractalkine

KW - Insulin

KW - Insulin secretion

KW - Islets

KW - β-cell

UR - http://www.scopus.com/inward/record.url?scp=84988530040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988530040&partnerID=8YFLogxK

U2 - 10.4161/isl.27861

DO - 10.4161/isl.27861

M3 - Comment/debate

C2 - 25483879

AN - SCOPUS:84988530040

VL - 6

JO - Islets

JF - Islets

SN - 1938-2014

IS - 1

M1 - e27861

ER -